Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy
- PMID: 9039220
- DOI: 10.1016/s0964-1955(96)00017-6
Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy
Abstract
CYFRA 21-1 is a fragment of cytokeratin expressed by simple epithelia and their malignant counter-parts. Serum CYFRA 21-1 levels were studied in 240 new cases of nasopharyngeal carcinoma and 19 patients who developed distant metastases. A reference range of < 2 U/ml for our local Chinese population was established in 55 sex- and age-matched healthy volunteers. The nasopharyngeal carcinoma patients had significantly higher marker levels than the healthy controls and the mean level increased with advancing stage. However, the low percentage of elevation in early stages means that the marker is not useful for screening. The overall percentage (52.5) of elevation in 240 newly diagnosed squamous cell carcinoma of the nasopharynx is comparable to that of squamous cell carcinoma of the lungs, suggesting that the expression of CYFRA 21-1 is related to the cell type rather than the tissue type of the carcinoma, 46 (95.8%) of 48 patients with metastatic nasopharyngeal carcinoma showed an elevated value of CYFRA 21-1. This extremely high percentage implies that it is very unlikely for a patient with a normal value to have distant metastasis. This may permit major economies in radiological screening for distant metastasis. Preliminary results from serial measurement of the marker indicated its potential for monitoring response to treatment and for early detection of distant metastasis.
Similar articles
-
Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.Oncology. 2002;63(3):280-5. doi: 10.1159/000065476. Oncology. 2002. PMID: 12381908
-
Prognostic value of the pretreatment serum level of cytokeratin fraction 21-1 in undifferentiated nasopharyngeal carcinoma: a study of 332 cases.Head Neck. 2014 Jan;36(1):71-6. doi: 10.1002/hed.23261. Epub 2013 Jun 1. Head Neck. 2014. PMID: 23728904
-
CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.Chest. 1996 Apr;109(4):995-1000. doi: 10.1378/chest.109.4.995. Chest. 1996. PMID: 8635383
-
Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.Ann Otol Rhinol Laryngol. 2001 Aug;110(8):775-8. doi: 10.1177/000348940111000814. Ann Otol Rhinol Laryngol. 2001. PMID: 11510737
-
[CYFRA 21-1 and bronchial cancer].Rev Mal Respir. 1995;12(6):533-41. Rev Mal Respir. 1995. PMID: 8677347 Review. French.
Cited by
-
Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors.Iran J Otorhinolaryngol. 2017 Jul;29(93):203-208. Iran J Otorhinolaryngol. 2017. PMID: 28819618 Free PMC article.
-
Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck.Med Oncol. 2006;23(4):463-70. doi: 10.1385/MO:23:4:463. Med Oncol. 2006. PMID: 17303904